vs
CBL & ASSOCIATES PROPERTIES INC（CBL）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Ultragenyx Pharmaceutical Inc.的季度营收约是CBL & ASSOCIATES PROPERTIES INC的1.3倍（$207.3M vs $156.4M），CBL & ASSOCIATES PROPERTIES INC净利率更高（31.3% vs -62.0%，领先93.3%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs 18.8%），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 10.1%）
CBL联合地产是一家美国房地产投资信托企业，核心投资布局为购物中心与商业摩尔，业务主要集中在美国东南部与中西部地区。公司在特拉华州注册，总部设于田纳西州查塔努加，该城市也是其最大的布局市场，公司名称取自创始人查尔斯·B·勒博维茨的姓名首字母。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
CBL vs RARE — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $156.4M | $207.3M |
| 净利润 | $49.0M | $-128.6M |
| 毛利率 | — | — |
| 营业利润率 | — | -54.7% |
| 净利率 | 31.3% | -62.0% |
| 营收同比 | 18.8% | 25.9% |
| 净利润同比 | 29.0% | 3.5% |
| 每股收益（稀释后） | $1.61 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $156.4M | $207.3M | ||
| Q3 25 | $139.3M | $159.9M | ||
| Q2 25 | $140.9M | $166.5M | ||
| Q1 25 | $141.8M | $139.3M | ||
| Q4 24 | $131.7M | $164.6M | ||
| Q3 24 | $125.1M | $139.5M | ||
| Q2 24 | $129.7M | $147.0M | ||
| Q1 24 | $129.1M | $108.8M |
| Q4 25 | $49.0M | $-128.6M | ||
| Q3 25 | $75.4M | $-180.4M | ||
| Q2 25 | $2.8M | $-115.0M | ||
| Q1 25 | $8.8M | $-151.1M | ||
| Q4 24 | $38.0M | $-133.2M | ||
| Q3 24 | $16.2M | $-133.5M | ||
| Q2 24 | $4.7M | $-131.6M | ||
| Q1 24 | $50.0K | $-170.7M |
| Q4 25 | — | -54.7% | ||
| Q3 25 | — | -106.9% | ||
| Q2 25 | — | -64.8% | ||
| Q1 25 | — | -102.6% | ||
| Q4 24 | — | -74.3% | ||
| Q3 24 | — | -94.6% | ||
| Q2 24 | — | -79.1% | ||
| Q1 24 | — | -151.9% |
| Q4 25 | 31.3% | -62.0% | ||
| Q3 25 | 54.2% | -112.8% | ||
| Q2 25 | 2.0% | -69.0% | ||
| Q1 25 | 6.2% | -108.5% | ||
| Q4 24 | 28.8% | -80.9% | ||
| Q3 24 | 12.9% | -95.7% | ||
| Q2 24 | 3.7% | -89.5% | ||
| Q1 24 | 0.0% | -156.8% |
| Q4 25 | $1.61 | $-1.28 | ||
| Q3 25 | $2.38 | $-1.81 | ||
| Q2 25 | $0.08 | $-1.17 | ||
| Q1 25 | $0.27 | $-1.57 | ||
| Q4 24 | $1.22 | $-1.34 | ||
| Q3 24 | $0.52 | $-1.40 | ||
| Q2 24 | $0.14 | $-1.52 | ||
| Q1 24 | $-0.01 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $42.3M | $421.0M |
| 总债务越低越好 | $2.2B | — |
| 股东权益账面价值 | $374.9M | $-80.0M |
| 总资产 | $2.7B | $1.5B |
| 负债/权益比越低杠杆越低 | 5.79× | — |
8季度趋势，按日历期对齐
| Q4 25 | $42.3M | $421.0M | ||
| Q3 25 | $52.6M | $202.5M | ||
| Q2 25 | $100.3M | $176.3M | ||
| Q1 25 | $100.3M | $127.1M | ||
| Q4 24 | $40.8M | $174.0M | ||
| Q3 24 | $65.1M | $150.6M | ||
| Q2 24 | $57.7M | $480.7M | ||
| Q1 24 | $57.7M | $112.3M |
| Q4 25 | $2.2B | — | ||
| Q3 25 | $2.2B | — | ||
| Q2 25 | $2.1B | — | ||
| Q1 25 | $2.2B | — | ||
| Q4 24 | $2.2B | — | ||
| Q3 24 | $1.8B | — | ||
| Q2 24 | $1.9B | — | ||
| Q1 24 | $1.9B | — |
| Q4 25 | $374.9M | $-80.0M | ||
| Q3 25 | $351.4M | $9.2M | ||
| Q2 25 | $289.4M | $151.3M | ||
| Q1 25 | $295.0M | $144.2M | ||
| Q4 24 | $323.5M | $255.0M | ||
| Q3 24 | $308.3M | $346.8M | ||
| Q2 24 | $308.8M | $432.4M | ||
| Q1 24 | $324.2M | $140.3M |
| Q4 25 | $2.7B | $1.5B | ||
| Q3 25 | $2.7B | $1.2B | ||
| Q2 25 | $2.6B | $1.3B | ||
| Q1 25 | $2.6B | $1.3B | ||
| Q4 24 | $2.7B | $1.5B | ||
| Q3 24 | $2.2B | $1.5B | ||
| Q2 24 | $2.3B | $1.6B | ||
| Q1 24 | $2.3B | $1.3B |
| Q4 25 | 5.79× | — | ||
| Q3 25 | 6.21× | — | ||
| Q2 25 | 7.39× | — | ||
| Q1 25 | 7.29× | — | ||
| Q4 24 | 6.84× | — | ||
| Q3 24 | 5.76× | — | ||
| Q2 24 | 6.00× | — | ||
| Q1 24 | 5.74× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $249.7M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | — | $-100.8M |
| 自由现金流率自由现金流/营收 | — | -48.6% |
| 资本支出强度资本支出/营收 | — | 0.5% |
| 现金转化率经营现金流/净利润 | 5.10× | — |
| 过去12个月自由现金流最近4个季度 | — | $-472.0M |
8季度趋势，按日历期对齐
| Q4 25 | $249.7M | $-99.8M | ||
| Q3 25 | $69.6M | $-91.4M | ||
| Q2 25 | $68.3M | $-108.3M | ||
| Q1 25 | $31.7M | $-166.5M | ||
| Q4 24 | $202.2M | $-79.3M | ||
| Q3 24 | $61.1M | $-67.0M | ||
| Q2 24 | $64.2M | $-77.0M | ||
| Q1 24 | $30.7M | $-190.7M |
| Q4 25 | — | $-100.8M | ||
| Q3 25 | — | $-92.7M | ||
| Q2 25 | — | $-110.7M | ||
| Q1 25 | — | $-167.8M | ||
| Q4 24 | — | $-79.5M | ||
| Q3 24 | $46.0M | $-68.6M | ||
| Q2 24 | $54.8M | $-79.0M | ||
| Q1 24 | $24.7M | $-193.9M |
| Q4 25 | — | -48.6% | ||
| Q3 25 | — | -58.0% | ||
| Q2 25 | — | -66.5% | ||
| Q1 25 | — | -120.5% | ||
| Q4 24 | — | -48.3% | ||
| Q3 24 | 36.8% | -49.2% | ||
| Q2 24 | 42.2% | -53.7% | ||
| Q1 24 | 19.1% | -178.2% |
| Q4 25 | — | 0.5% | ||
| Q3 25 | — | 0.8% | ||
| Q2 25 | — | 1.5% | ||
| Q1 25 | — | 1.0% | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | 12.1% | 1.2% | ||
| Q2 24 | 7.3% | 1.4% | ||
| Q1 24 | 4.7% | 3.0% |
| Q4 25 | 5.10× | — | ||
| Q3 25 | 0.92× | — | ||
| Q2 25 | 24.74× | — | ||
| Q1 25 | 3.60× | — | ||
| Q4 24 | 5.32× | — | ||
| Q3 24 | 3.77× | — | ||
| Q2 24 | 13.54× | — | ||
| Q1 24 | 614.76× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CBL
暂无分部数据
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
